NFL is a marker of treatment response in children with SMA treated with nusinersen
ConclusionsNusinersen normalized the axonal damage marker NFL and correlated with motor improvement in children with SMA. NFL may, therefore, be a novel biomarker to monitor treatment response early in the disease course.
Source: Journal of Neurology - Category: Neurology Source Type: research
More News: Brain | Children | Genetics | Infectious Diseases | Neurology | Spinal Muscular Atrophy | Study